Apollomics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
APLM Nasdaq 2834 www.apollomicsinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apollomics, Inc.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - Oct 15th, 2025 12:36 pm
Apollomics, Inc. Company Operational Continuity Update - Oct 13th, 2025 7:22 pm
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - Apr 3rd, 2025 2:05 pm
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - Mar 31st, 2025 6:00 am
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Dec 20th, 2024 6:00 am
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - Dec 10th, 2024 2:05 pm
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - Nov 21st, 2024 6:00 am